226 related articles for article (PubMed ID: 31494475)
1. Natural products as important tyrosine kinase inhibitors.
Yin B; Fang DM; Zhou XL; Gao F
Eur J Med Chem; 2019 Nov; 182():111664. PubMed ID: 31494475
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Biological Evaluation of Novel 4,5,6,7-Tetrahydrobenzo[D]-Thiazol-2- Yl Derivatives Derived from Dimedone with Anti-Tumor, C-Met, Tyrosine Kinase and Pim-1 Inhibitions.
Mohareb RM; Abouzied AS; Abbas NS
Anticancer Agents Med Chem; 2019; 19(12):1438-1453. PubMed ID: 31038076
[TBL] [Abstract][Full Text] [Related]
3. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Sakle NS; More SA; Dhawale SA; Mokale SN
Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
[TBL] [Abstract][Full Text] [Related]
4. Anchor-based classification and type-C inhibitors for tyrosine kinases.
Hsu KC; Sung TY; Lin CT; Chiu YY; Hsu JT; Hung HC; Sun CM; Barve I; Chen WL; Huang WC; Huang CT; Chen CH; Yang JM
Sci Rep; 2015 Jun; 5():10938. PubMed ID: 26077136
[TBL] [Abstract][Full Text] [Related]
5. Curcumin as tyrosine kinase inhibitor in cancer treatment.
Golonko A; Lewandowska H; Świsłocka R; Jasińska UT; Priebe W; Lewandowski W
Eur J Med Chem; 2019 Nov; 181():111512. PubMed ID: 31404861
[TBL] [Abstract][Full Text] [Related]
6. Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents.
Nandi S; Dey R; Samadder A; Saxena A; Saxena AK
Curr Med Chem; 2022; 29(2):212-234. PubMed ID: 33655823
[TBL] [Abstract][Full Text] [Related]
7. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs.
Wang X; Xu L; Lao Y; Zhang H; Xu H
Curr Protein Pept Sci; 2018 Feb; 19(4):380-388. PubMed ID: 28059040
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents.
Guo T; Ma S
ChemMedChem; 2021 Feb; 16(4):600-620. PubMed ID: 33179854
[TBL] [Abstract][Full Text] [Related]
9. "Discovery and development of new anticancer drugs inspired from natural product leads" part 1.
Rane R; Karpoormath R
Anticancer Agents Med Chem; 2015; 15(5):536. PubMed ID: 25981059
[No Abstract] [Full Text] [Related]
10. Screening of break point cluster region Abelson tyrosine kinase inhibitors by capillary electrophoresis.
Xu M; Zheng M; Liu G; Zhang M; Kang J
J Chromatogr A; 2018 Feb; 1537():128-134. PubMed ID: 29336809
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin: a recent perspective.
Patel HM; Rane R; Thapliyal N; Palkar M; Shaikh M; Karpoormath R
Anticancer Agents Med Chem; 2015; 15(8):988-1011. PubMed ID: 25763933
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase inhibitors in the management of cancer: therapeutic opportunities from natural compounds.
Singh H; Kumar R; Mazumder A
J Asian Nat Prod Res; 2024 Jun; 26(6):663-680. PubMed ID: 38373215
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
Huang L; Jiang S; Shi Y
J Hematol Oncol; 2020 Oct; 13(1):143. PubMed ID: 33109256
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.
Gallick GE; Corn PG; Zurita AJ; Lin SH
Future Med Chem; 2012 Jan; 4(1):107-19. PubMed ID: 22168167
[TBL] [Abstract][Full Text] [Related]
16. Metabolomics: a tool for anticancer lead-finding from natural products.
Kim HK; Wilson EG; Choi YH; Verpoorte R
Planta Med; 2010 Aug; 76(11):1094-102. PubMed ID: 20486069
[TBL] [Abstract][Full Text] [Related]
17. Prospective Plant Based Anticancer Lead Molecules.
Kaur P; Sharma V
Curr Top Med Chem; 2018; 18(30):2567-2583. PubMed ID: 30582476
[TBL] [Abstract][Full Text] [Related]
18. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
[TBL] [Abstract][Full Text] [Related]
19. In silico identification of natural products with anticancer activity using a chemo-structural database of Brazilian biodiversity.
Galúcio JM; Monteiro EF; de Jesus DA; Costa CH; Siqueira RC; Santos GBD; Lameira J; Costa KSD
Comput Biol Chem; 2019 Dec; 83():107102. PubMed ID: 31487609
[TBL] [Abstract][Full Text] [Related]
20. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
